Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 7, 2000, Pages 1921-1924

  Hershberger, Ellie ^a,b   Coyle, Elizabeth A ^a,b   Kaatz, Glenn W ^b,c,d   Zervos, Marcus J ^c,e   Rybak, Michael J ^a,b,c  

^a DETROIT RECEIVING HOSPITAL   (United States)

^b WSU   (United States)

^c Henry Ford Health System Division of Infectious Diseases   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; METICILLIN; SPARFLOXACIN; TROVAFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RABBIT; SPECIES DIFFERENCE; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE;

ANIMAL TESTING ALTERNATIVES; ANIMALS; ANTI-INFECTIVE AGENTS; BLOOD PLATELETS; CATTLE; CIPROFLOXACIN; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; RABBITS; STAPHYLOCOCCUS AUREUS;

EID: 0033936491     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.7.1921-1924.2000     Document Type: Article

References (7)

1. Kaatz, G. W., S. M. Seo, J. R. Aeschlimann, H. H. Houlihan, R. C. Mercier, and M. J. Rybak. 1998. Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 42:254-256.
2. Kaatz, G. W., S. M. Seo, S. L. Barriere, L. M. Albrecht, and M. J. Rybak. 1989. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 33:1184-1187.
3. Kaatz, G. W., S. M. Seo, S. L. Barriere, D. R. Schaberg, and R. Fekety. 1987. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 31:527-530.
4. Kaatz, G. W., S. M. Seo, K. C. Lamp, E. M. Bailey, and M. J. Rybak. 1992. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 36:1192-1197.
5. McGrath, B. J., S. L. Kang, G. W. Kaatz, and M. J. Rybak. 1994. Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis. Antimicrob. Agents Chemother. 38:2034-2040.
6. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Wayne, Pa.
7. Vazquez, J., M. B. Perri, L. A. Thal, S. Donabedian, and M. J. Zervos. 1993. Sparfloxacin and clinafloxacin alone or in combination with gentamicin for therapy of experimental ampicillin-resistant enterococcal endocarditis in rabbits. J. Antimicrob. Chemother. 32:715-721.